- 南开大学医学院,天津 300350
摘要
- Nankai University School of Medicine, Tianjin 300350, China
Abstract
Objective To explore a novel therapeutic strategy for acute lung injury (ALI) with high efficacy and favorable clinical translational potential by delivering mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) via the intranasal route and to systematically evaluate the therapeutic effects of MSC-EVs in a lipopolysaccharide ( LPS) induced ALI model and further provided initial insights into the underlying mechanisms. Methods MSC-EVs were isolated and characterized from the conditioned medium of human umbilical cord MSCs (hUC-MSCs). Following the establishment of a mouse ALI model via intratracheal instillation of LPS, the intervention was administered through intranasal inhalation. Twenty-four hours post-intervention, a comprehensive assessment of therapeutic efficacy was conducted. This included histological evaluation of lung tissues via hematoxylin-eosin (HE) staining, immunofluorescence staining, cytological and biochemical analysis of bronchoalveolar lavage fluid (BALF), and quantification of the inflammatory cytokine interleukin-6 (IL-6) using real-time reverse transcription quantitative polymerase chain reaction (RT-PCR). Furthermore, bioinformatics approaches were employed to predict the target genes of key microRNAs ( miRNAs) contained within the MSC-EVs. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was subsequently performed to explore the potential molecular network mechanisms underlying their therapeutic effects. Results Intranasal inhalation of MSC-EVs significantly ameliorated pulmonary histopathological damage in ALI mice. Compared to the injury group, the MSC-EVs treatment group showed marked improvements in lung histopathology and the extent of immune cell infiltration following injury. Bioinformatics analysis revealed that the miRNAs enriched in MSC-EVs may participate in processes such as inflammation suppression, apoptosis regulation, and tissue repair, potentially by modulating key signaling pathways including mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)-protein kenase B (PKB/ Akt). Conclusion This study systematically demonstrates that intranasal inhalation effectively delivers MSC-EVs to the lungs. The therapeutic effects are closely associated with direct attenuation of pulmonary pathological damage, modulation of local immune responses, and regulation of multiple repair-related signaling pathways. Collectively, these findings provide important experimental evidence and novel insights for the development of MSC-EV-based inhalable biologics and for advancing the clinical treatment of ALI.
